Intravesical interleukin-2 in T1 papillary bladder carcinoma: Regression of marker lesion in 8 of 10 patients
Intravesical interleukin-2 in T1 papillary bladder carcinoma: Regression of marker lesion in 8 of 10 patients
复制标题
DOI：
10.1016/s0022-5347(01)63548-1
复制
发表时间：
1998-04-01
影响因子：
6.6
通讯作者：
Zembala, M
中科院分区：
文献类型：
--
作者：
Den Otter, W;Dobrowolski, Z;Zembala, M
目的：我们评估膀胱内白细胞介素-2（IL-2）对T1乳头状膀胱癌不完全经尿道切除术后的治疗效果。材料和方法：不完全经尿道切除术后，我们治疗了10例标记病变留在原位的患者，其中3 × 10（6）Chiron单位IL-2在50分钟。生理盐水加0.1%人血清白蛋白。该溶液在膀胱中保留2小时，并连续5天滴注。治疗后2个月，通过膀胱镜检查和标记部位的重复活检评估IL-2治疗对标记病变的影响。此外，对膀胱肿瘤复发的影响进行了研究。结果：在2个月的10个标记病变（80%）8完全消退，并有重复活检没有肿瘤细胞。4名患者在30至54个月后保持无肿瘤。我们没有注意到任何毒性作用。在1例有7年膀胱癌病史的患者中，该标记物在2个月后仅部分消退。去除后的标记，这名患者保持无肿瘤，在后续的54 months.Conclusions：据我们所知，这份报告是第一次研究的IL-2标记病变后，经尿道切除术的影响。结果表明，IL-2滴注是可行的，经尿道电切联合IL-2滴注可能具有强大的抗肿瘤作用。治疗效果可能不仅仅是由于膀胱内IL-2，因为先前的经尿道切除术可能引起一些浸润细胞的流入，并且标记物可能具有肿瘤相关抗原。因此，这些作用可能是由于肿瘤相关抗原、浸润细胞和IL-2的相互作用。
Purpose: We evaluate the therapeutic effect of intravesical interleukin-2 (IL-2) on T1 papillary bladder carcinoma after incomplete transurethral resection.Materials and Methods: After incomplete transurethral resection we treated 10 patients in whom the marker lesion was left in place with 3 x 10(6) Chiron units IL-2 in 50 mi. saline plus 0.1% human serum albumin. The solution remained in the bladder for 2 hours and it was instilled on 5 consecutive days. The effect of IL-2 treatment on the marker lesion was evaluated by cystoscopy and repeat biopsy of the marker site 2 months after treatment. In addition, the effect on the recurrence of bladder tumors was studied.Results: At 2 months 8 of the 10 marker lesions (80%) had completely regressed and there were no tumor cells on repeat biopsy. Four patients remained tumor-free after 30 to 54 months. We noted no toxic effects. In 1 patient with a 7-year history of bladder cancer the marker was only partially regressed after 2 months. After removal of the marker this patient remained tumor-free at a followup of 54 months.Conclusions: To our knowledge this report represents the first study of the effect of IL-2 on marker lesions left in place after transurethral resection. The results indicate that IL-2 instillations are feasible, and the combination of transurethral resection and IL-2 instillation may have a powerful antitumor effect. The therapeutic effects may not simply be due to intravesical IL-2, because previous transurethral resection probably caused some influx of infiltrating cells and the marker may have had tumor associated antigens. Consequently these effects may be due to the interaction of tumor associated antigens, infiltrating cells and IL-2.